An indolylquinoline derivative activates DNA damage response and apoptosis in human hepatocellular carcinoma cells

Chun Yen Liu, Chang Hung Hsieh, Seung Hun Kim, Jing Ping Wang, Yu Lin Ni, Chun Li Su, Ching Fa Yao, Kang Fang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Human liver cancer is one of the most frequently diagnosed cancers worldwide. The development of resistance to therapy limits the application against the disease. To improve treatment, new effective anticancer agents are constantly pursued. Previously, we reported that an indolylquinoline, 3-((7-ethyl-1H-indol-3-yl)-methyl)-2-methylquinoline (EMMQ), is effective in suppressing the growth of human lung cancer by impairing mitochondria functions. The present study revealed that EMMQ inhibited cell growth and induced apoptosis in liver cancer cells, but not in normal cells. This study demonstrated that EMMQ induced DNA damage by activating p53 and H2AX and cell arrest by suppressing cyclin D1 and CDK2. Damaged DNA injured mitochondrial functions by lowering the membrane potential and producing reactive oxygen species. The subsequent mitochondrial cytochrome c release attenuated pro-survival signals and increased apoptotic characteristics. Introduction of p53 shRNA abrogated drug effects by reducing DNA damage while maintaining mitochondria integrity. In brief, the study demonstrates that the effectiveness of EMMQ accentuated apoptosis of hepatocarcinoma cells by activating p53. Based on these collective findings, the study offered a new perspective of EMMQ that was shown to be a promising candidate to treat liver cancer.

Original languageEnglish
Pages (from-to)2431-2441
Number of pages11
JournalInternational Journal of Oncology
Volume49
Issue number6
DOIs
Publication statusPublished - 2016 Dec

Fingerprint

DNA Damage
Hepatocellular Carcinoma
Apoptosis
Liver Neoplasms
Mitochondria
Cyclin D1
Growth
Cytochromes c
Mitochondrial DNA
Antineoplastic Agents
Membrane Potentials
Small Interfering RNA
Reactive Oxygen Species
Lung Neoplasms
Survival
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Apoptosis
  • Human liver cancer cells
  • Indolylquinoline

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

An indolylquinoline derivative activates DNA damage response and apoptosis in human hepatocellular carcinoma cells. / Liu, Chun Yen; Hsieh, Chang Hung; Kim, Seung Hun; Wang, Jing Ping; Ni, Yu Lin; Su, Chun Li; Yao, Ching Fa; Fang, Kang.

In: International Journal of Oncology, Vol. 49, No. 6, 12.2016, p. 2431-2441.

Research output: Contribution to journalArticle

Liu, Chun Yen ; Hsieh, Chang Hung ; Kim, Seung Hun ; Wang, Jing Ping ; Ni, Yu Lin ; Su, Chun Li ; Yao, Ching Fa ; Fang, Kang. / An indolylquinoline derivative activates DNA damage response and apoptosis in human hepatocellular carcinoma cells. In: International Journal of Oncology. 2016 ; Vol. 49, No. 6. pp. 2431-2441.
@article{3d69995265804cf7878ba19fb20b9cd1,
title = "An indolylquinoline derivative activates DNA damage response and apoptosis in human hepatocellular carcinoma cells",
abstract = "Human liver cancer is one of the most frequently diagnosed cancers worldwide. The development of resistance to therapy limits the application against the disease. To improve treatment, new effective anticancer agents are constantly pursued. Previously, we reported that an indolylquinoline, 3-((7-ethyl-1H-indol-3-yl)-methyl)-2-methylquinoline (EMMQ), is effective in suppressing the growth of human lung cancer by impairing mitochondria functions. The present study revealed that EMMQ inhibited cell growth and induced apoptosis in liver cancer cells, but not in normal cells. This study demonstrated that EMMQ induced DNA damage by activating p53 and H2AX and cell arrest by suppressing cyclin D1 and CDK2. Damaged DNA injured mitochondrial functions by lowering the membrane potential and producing reactive oxygen species. The subsequent mitochondrial cytochrome c release attenuated pro-survival signals and increased apoptotic characteristics. Introduction of p53 shRNA abrogated drug effects by reducing DNA damage while maintaining mitochondria integrity. In brief, the study demonstrates that the effectiveness of EMMQ accentuated apoptosis of hepatocarcinoma cells by activating p53. Based on these collective findings, the study offered a new perspective of EMMQ that was shown to be a promising candidate to treat liver cancer.",
keywords = "Apoptosis, Human liver cancer cells, Indolylquinoline",
author = "Liu, {Chun Yen} and Hsieh, {Chang Hung} and Kim, {Seung Hun} and Wang, {Jing Ping} and Ni, {Yu Lin} and Su, {Chun Li} and Yao, {Ching Fa} and Kang Fang",
year = "2016",
month = "12",
doi = "10.3892/ijo.2016.3717",
language = "English",
volume = "49",
pages = "2431--2441",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - An indolylquinoline derivative activates DNA damage response and apoptosis in human hepatocellular carcinoma cells

AU - Liu, Chun Yen

AU - Hsieh, Chang Hung

AU - Kim, Seung Hun

AU - Wang, Jing Ping

AU - Ni, Yu Lin

AU - Su, Chun Li

AU - Yao, Ching Fa

AU - Fang, Kang

PY - 2016/12

Y1 - 2016/12

N2 - Human liver cancer is one of the most frequently diagnosed cancers worldwide. The development of resistance to therapy limits the application against the disease. To improve treatment, new effective anticancer agents are constantly pursued. Previously, we reported that an indolylquinoline, 3-((7-ethyl-1H-indol-3-yl)-methyl)-2-methylquinoline (EMMQ), is effective in suppressing the growth of human lung cancer by impairing mitochondria functions. The present study revealed that EMMQ inhibited cell growth and induced apoptosis in liver cancer cells, but not in normal cells. This study demonstrated that EMMQ induced DNA damage by activating p53 and H2AX and cell arrest by suppressing cyclin D1 and CDK2. Damaged DNA injured mitochondrial functions by lowering the membrane potential and producing reactive oxygen species. The subsequent mitochondrial cytochrome c release attenuated pro-survival signals and increased apoptotic characteristics. Introduction of p53 shRNA abrogated drug effects by reducing DNA damage while maintaining mitochondria integrity. In brief, the study demonstrates that the effectiveness of EMMQ accentuated apoptosis of hepatocarcinoma cells by activating p53. Based on these collective findings, the study offered a new perspective of EMMQ that was shown to be a promising candidate to treat liver cancer.

AB - Human liver cancer is one of the most frequently diagnosed cancers worldwide. The development of resistance to therapy limits the application against the disease. To improve treatment, new effective anticancer agents are constantly pursued. Previously, we reported that an indolylquinoline, 3-((7-ethyl-1H-indol-3-yl)-methyl)-2-methylquinoline (EMMQ), is effective in suppressing the growth of human lung cancer by impairing mitochondria functions. The present study revealed that EMMQ inhibited cell growth and induced apoptosis in liver cancer cells, but not in normal cells. This study demonstrated that EMMQ induced DNA damage by activating p53 and H2AX and cell arrest by suppressing cyclin D1 and CDK2. Damaged DNA injured mitochondrial functions by lowering the membrane potential and producing reactive oxygen species. The subsequent mitochondrial cytochrome c release attenuated pro-survival signals and increased apoptotic characteristics. Introduction of p53 shRNA abrogated drug effects by reducing DNA damage while maintaining mitochondria integrity. In brief, the study demonstrates that the effectiveness of EMMQ accentuated apoptosis of hepatocarcinoma cells by activating p53. Based on these collective findings, the study offered a new perspective of EMMQ that was shown to be a promising candidate to treat liver cancer.

KW - Apoptosis

KW - Human liver cancer cells

KW - Indolylquinoline

UR - http://www.scopus.com/inward/record.url?scp=84996537971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996537971&partnerID=8YFLogxK

U2 - 10.3892/ijo.2016.3717

DO - 10.3892/ijo.2016.3717

M3 - Article

C2 - 27748837

AN - SCOPUS:84996537971

VL - 49

SP - 2431

EP - 2441

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -